Free shipping on all orders over $ 500

Crovalimab

Cat. No. M24849

All AbMole products are for research use only, cannot be used for human consumption.

Crovalimab Structure
Synonym:

SKY59; RO7112689

Size Price Availability Quantity
100ug USD 170  USD170 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research.

Chemical Information
CAS Number 1917321-26-6
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
References

[1] Masanobu Nishidate, et al. Bioanalysis. Validation of a method to analyze size distribution of crovalimab-complement C5-eculizumab complexes in human serum

[2] Gianluigi Ardissino, et al. Pharmaceuticals (Basel). Complement System as a New Target for Hematopoietic Stem Cell Transplantation-Related Thrombotic Microangiopathy

[3] Urszula Szlendak, et al. Pol Arch Intern Med. Paroxysmal nocturnal hemoglobinuria: advances in the understanding of pathophysiology, diagnosis, and treatment

[4] Jun-Ichi Nishimura, et al. Br J Haematol. Crovalimab for treatment of patients with paroxysmal nocturnal haemoglobinuria and complement C5 polymorphism: Subanalysis of the phase 1/2 COMPOSER study

[5] Alexander Röth, et al. Blood. The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria

Related Complement System Products
JPE-1375

JPE-1375 is a complement C5a receptor 1 (C5aR1) antagonist. JPE-1375 effectively inhibits polymorphonuclear leukocyte mobilization (EC50=6.9 µM) and reduces TNF levels (EC50=4.5 µM) in mice.

C5aR-IN-1 

C5aR-IN-1 is a potent inhibitor of C5aR.

EG01377 dihydrochloride 

EG01377 dihydrochloride is a potent, bioavailable and selective inhibitor of neuropilin-1 (NRP1), with a Kd of 1.32 μM, and IC50s of 609 nM for both NRP1-a1 and NRP1-b1.

Empasiprubart

Empasiprubar (ARGX-117) is a humanized inhibitory monoclonal antibody targeting complement C2. Empasiprubar binds to the Sushi-2 domain of C2, preventing the formation of C3 pre convertase and inhibiting the activation of classical and lectin pathways upstream of C3 activation.

Avacincaptad pegol sodium

Avacincaptad pegol (ARC1905) is an anti-C5 RNA aptamer that inhibits the cleavage of complement factor 5 (C5) into C5a and C5b.

  Catalog
Abmole Inhibitor Catalog




Keywords: Crovalimab, SKY59; RO7112689 supplier, Complement System, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.